Chika Inadomi
Overview
Explore the profile of Chika Inadomi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kubotsu Y, Sakamoto Y, Tago M, Chihara A, Norita M, Inadomi C, et al.
J Atheroscler Thromb
. 2024 Sep;
32(2):239-252.
PMID: 39231650
Aims: Cardiovascular disease (CVD) is a common cause of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, CVD surveillance is important, but it is not well established....
2.
Zhao W, Mori H, Tomiga Y, Tanaka K, Perveen R, Mine K, et al.
Genes (Basel)
. 2022 Jul;
13(7).
PMID: 35886046
There is an association between nonalcoholic fatty liver disease (NAFLD) and atherosclerosis, but the genetic risk of atherosclerosis in NAFLD remains unclear. Here, a single-nucleotide polymorphism (SNP) of the heat...
3.
Kimura S, Tanaka K, Oeda S, Inoue K, Inadomi C, Kubotsu Y, et al.
Sci Rep
. 2021 Aug;
11(1):15641.
PMID: 34341368
The effect of the skin-capsular distance (SCD) on the controlled attenuation parameter (CAP) for diagnosis of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD) remains unclear. The SCD...
4.
Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, et al.
Diagnostics (Basel)
. 2021 Jan;
11(1).
PMID: 33467114
Access to imaging is limited for diagnosing nonalcoholic fatty liver disease (NAFLD) in general populations. This study evaluated the diagnostic performance of noninvasive and nonimaging indexes to predict NAFLD in...
5.
Inadomi C, Takahashi H, Ogawa Y, Oeda S, Imajo K, Kubotsu Y, et al.
Hepatol Res
. 2020 Feb;
50(6):682-692.
PMID: 32090397
Aim: The Enhanced Liver Fibrosis (ELF) test comprises a logarithmic algorithm combining three serum markers of hepatic extracellular matrix metabolism. We aimed to evaluate the performance of ELF for the...